The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Mutations truncating the EP300 acetylase in human cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884 · cited 1×
“that regulates transcription via chromatin remodellin”
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
Self-citationDNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,136
Self-citationYao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81165-4 · Cited by 1,014
Binding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
Recruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Lundblad, J. R., Kwok, R. P. S., Laurance, M. E., Harter, M. L., & Goodman, R. H. (1995) · Nature · doi:10.1038/374085a0 · Cited by 588
Cited by
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
“Muroaka et al. (1996) identified p300 missense mutations associated with loss of heterozygosity in tumors from two patients, one with colorectal and the other with gastric carcinoma, and Gayther et al. (2000) recently reported five additional examples.”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
“Missense point mutations in p300 are found in colorectal adenocarcinoma, gastric adenocarcinoma and breast cancer with quite low incidences.(186,187) Rare inactivating mutations in CBP and PCAF have only been identified in cancer cell lines but not primary tumors.”
BackgroundCawley, S., Bekiranov, S., Ng, H. H., Kapranov, P., Sekinger, E. A., Kampa, D., Piccolboni, A., Sementchenko, V., Cheng, J., Williams, A. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00127-8 · Cited by 1,095
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
Histone Modifications and Cancer
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 910
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2002) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Iyer, N. G., Özdag, H., & Caldas, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207118 · Cited by 638
Self-citationAberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 618
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2
Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., & Yao, T.-P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1331 · Cited by 582
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Yang, X.-J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh252 · Cited by 515
CBP and p300: HATs for different occasions
Kalkhoven, E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.045 · Cited by 496
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Resveratrol as an anticancer nutrient: molecular basis, open questions and promises
Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Liu, X., Wang, L., Zhao, K., Thompson, P. R., Hwang, Y., Marmorstein, R., & Cole, P. A. (2008) · Nature · doi:10.1038/nature06546 · Cited by 448
Roninson, I. B. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00847-3 · Cited by 443
Regulation of the p300 HAT domain via a novel activation loop
Thompson, P. R., Wang, D., Wang, L., Fulco, M., Pediconi, N., Zhang, D., An, W., Ge, Q., Roeder, R. G., Wong, J., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb740 · Cited by 423
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Histone acetyltransferases: function, structure, and catalysis
Marmorstein, R., & Roth, S. Y. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00173-8 · Cited by 401
The p53 pathway in breast cancer
Gasco, M., Shami, S., & Crook, T. (2002) · Breast Cancer Research · doi:10.1186/bcr426 · Cited by 393
Cellular transformation by SV40 large T antigen: interaction with host proteins
Ali, S. H., & DeCaprio, J. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0342 · Cited by 367
Weichert, W., Röske, A., Niesporek, S., Noske, A., Buckendahl, A.-C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 361
Bouras, T., Fu, M., Sauve, A. A., Wang, F., Quong, A. A., Perkins, N. D., Hay, R. T., Gu, W., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408748200 · Cited by 355
Histone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
Chromatin modifier enzymes, the histone code and cancer
Santos-Rosa, H., & Caldas, C. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.010 · Cited by 337
Self-citationp53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
RUNX transcription factors as key targets of TGF-β superfamily signaling
Ito, Y., & Miyazono, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00007-8 · Cited by 324
Chin, S. F., Teschendorff, A. E., Marioni, J. C., Wang, Y., Barbosa-Morais, N. L., Thorne, N. P., Costa, J. L., Pinder, S. E., van de Wiel, M. A., Green, A. R., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-10-r215 · Cited by 324
Self-citationDNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 319
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Histone acetyl transferases as emerging drug targets
Dekker, F. J., & Haisma, H. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.008 · Cited by 315
Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent
Chang, B.-D., Swift, M. E., Shen, M., Fang, J., Broude, E. V., & Roninson, I. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012602599 · Cited by 312
Adenovirus-5 E1A: paradox and paradigm
Frisch, S. M., & Mymryk, J. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm827 · Cited by 308
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Loughery, J., Cox, M., Smith, L. M., & Meek, D. W. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku501 · Cited by 305
Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E., & Panne, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2642 · Cited by 303
Nuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 302
Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., & Dentin, R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41624 · Cited by 300
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Esteller, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602918 · Cited by 284
Acetylation control of the retinoblastoma tumour-suppressor protein
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C., & Thangue, N. B. L. (2001) · Nature Cell Biology · doi:10.1038/35083062 · Cited by 282
Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis
Herceg, Z., & Hainaut, P. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.004 · Cited by 282
Jia, P., Zheng, S., Long, J., Zheng, W., & Zhao, Z. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btq615 · Cited by 282
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 262
Differential expression of selected histone modifier genes in human solid cancers
Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 259
Self-citationHistone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Cancers with wrong HATs: the impact of acetylation
Di Cerbo, V., & Schneider, R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els065 · Cited by 178
Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145
Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3
Kumar, A., Zhao, Y., Meng, G., Zeng, M., Srinivasan, S., Delmolino, L. M., Gao, Q., Dimri, G., Weber, G. F., Wazer, D. E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5801-5812.2002 · Cited by 131
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
Histone modifications as a pathogenic mechanism of colorectal tumorigenesis
Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53
Insights into regulators of p53 acetylation
Nagasaka, M., Miyajima, C., Aoki, H., Aoyama, M., Morishita, D., Inoue, Y., & Hayashi, H. (2022) · Cells · doi:10.3390/cells11233825 · Cited by 45
P300 regulates the human RLIP76 promoter activity and gene expression
Sehrawat, A., Yadav, S., Awasthi, Y. C., Basu, A., Warden, C., & Awasthi, S. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.012 · Cited by 14
Metadata
- Authors
- Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., Delhanty, J. D. A., Ponder, B. A. J., Kouzarides, T., & Caldas, C.
- Venue
- Nature Genetics
- Published
- 2000-03
- Volume
- 24
- Issue
- 3
- Pages
- 300-303
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1975232450
- Cited by
- 587
- References
- 18
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.